Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca's purchase of MedImmune cleared by U.S.

AstraZeneca Plc’s $15.2 billion purchase of MedImmune Inc., a biotechnology company with 45 drugs under development, was cleared by U.S. antitrust enforcers.

The proposed MedImmune acquisition by London-based AstraZeneca appeared on a list of completed government merger reviews published by the Federal Trade Commission in Washington.

MedImmune, which makes FluMist influenza vaccine and an antiviral treatment for babies, put itself up for sale April 12 under pressure from shareholders including Carl Icahn.

On April 30, MedImmune, based in Gaithersburg, said first-quarter profits more than tripled as sales rose 15 percent and expenses fell 20 percent during the period.

Shares of MedImmune rose 15 cents to $57.88 in composite Nasdaq Stock Market trading as of 4 p.m. New York time. AstraZeneca shares dropped 10 pence to 2693 pence in London trading.